Product/Composition:- | Sacubitril + Valsartan tablet |
---|---|
Strength:- | 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg |
Form:- | Tablet |
Reference Brands:- | Entresto: (US and EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sacubitril + Valsartan tablets combine an angiotensin receptor blocker with a neprilysin inhibitor, boosting natriuretic peptides and reducing blood pressure. They improve heart failure symptoms, decrease hospitalizations, and enhance survival rates. Benefits include better cardiac function, reduced strain, and improved quality of life for heart failure patients.
Sacubitril + Valsartan tablets, marketed as Entresto, are approved in the US by the FDA and in the EU via EMA for heart failure with reduced ejection fraction. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and post-market surveillance plans. In the US, the FDA reviews detailed clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance supports timely approval, safe use, and global availability of sacubitril/valsartan tablets, helping improve outcomes for heart failure patients worldwide.